Biomerica, Inc.
BMRA
NASDAQ·Healthcare·Medical - Devices·Mkt cap $6.6M
$2.14
▲ +1.90%
P/E
-2.04
Mkt Cap
$6.6M
52-Wk Range
$1.45–$3.22
52-Week Range
$1.45 - $3.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 31.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established 50+ year history with proven manufacturing expertise
- Proprietary diagnostic and therapeutic technologies
- Diversified distribution channels across physician offices, retail, and clinical laboratories
- Rapid product development capability demonstrated during pandemic response
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
No forward estimates available
Rising global demand for point-of-care diagnostic testing
Value
Valuation data unavailable
Momentum
Weak
-10.5% over 3m
Quality
Thin
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying BMRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 27, 2026
Most recent quarter reported revenue of $987.0K (-12% YoY). Reported EPS of -$0.44. Gross margin -4.5%.
Reported EPS · last 4Q
Q3 26
-$0.44
Q2 25
-$0.45
Q1 25
$0.00
Q4 25
-$0.16
Revenue trend · last 8Q
—
—
—
—
-33%
-24%
-26%
-12%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$1.1M
$1.8M
$1.6M
$1.1M
$749.0K
$1.4M
$1.2M
$987.0K
Margins · last 8Q
Gross
-4.5%
Operating
-131.5%
Profit
-132.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BMRA stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related